Europäische Union - Slowenisch - EMA (European Medicines Agency)

pharmaand gmbh - rucaparib camsylate - ovarijske neoplazme - antineoplastična sredstva - rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. rubraca je označen kot monotherapy za vzdrževanje zdravljenje odraslih bolnikov s platino-občutljive relapsed visoko-kakovostni razred epitelnih jajčnikov, fallopian tube, ali primarni trebušno raka, ki so v odziv (popolna ali delna) platinum, ki temelji kemoterapijo.

Europäische Union - Slowenisch - EMA (European Medicines Agency)

mylan pharmaceuticals limited - gefitinib - karcinom, pljučni pljuč - antineoplastic agents, protein kinase inhibitors - gefitinib mylan je označen kot monotherapy za zdravljenje odraslih bolnikov z lokalno napredno ali metastatskim non‑small cell lung cancer (nsclc) z aktiviranjem mutacije z egfr‑tk.

Europäische Union - Slowenisch - EMA (European Medicines Agency)

seqirus netherlands b.v. - a/darwin/6/2021(h3n2)-like strain (a/darwin/11/2021, wild type) / a/wisconsin/67/2022 (h1n1)pdm09-like strain (a/georgia/12/2022 cvr-167) / b/austria/1359417/2021-like strain (b/singapore/wuh4618/2021) / b/phuket/3073/2013-like virus (b/singapore/inftt-16-0610/2016, wild type) - gripa, človek - gripi, inaktivirano, split virus ali površinski antigen - prophylaxis of influenza in adults and children from 2 years of age. flucelvax tetra je treba uporabljati v skladu z uradnimi priporočili.

Europäische Union - Slowenisch - EMA (European Medicines Agency)

krka, d.d., novo mesto - atazanavir (as sulfate) - okužbe z virusom hiv - antivirusi za sistemsko uporabo - atazanavir krka kapsule, co-daje z nizkim odmerkom ritonavir, so označeni za zdravljenje okužbe z virusom hiv-1 okuženih odraslih in pediatričnih bolnikih 6 let starosti in starejših v kombinaciji z drugimi protiretrovirusnimi zdravili. na podlagi razpoložljivih virological in kliničnih podatkov odraslih bolnikih, nobene koristi ni pričakovati pri bolnikih s sevi, odporni na več protease inhibitorji (≥ 4 pi mutacije). izbira atazanavir krka se je v zdravljenje izkušenih odraslih in pediatričnih bolnikih mora temeljiti na posameznih virusnih odpornost testiranje in bolnika v zdravljenje zgodovina.

Europäische Union - Slowenisch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - afoxolaner - ektoparaziticidi za sistemsko uporabo - psi - zdravljenje bolh (ctenocephalides felis in c. canis) infestations. izdelek se lahko uporablja kot del strategije zdravljenja za nadzor alergijskega dermatitisa bolha (fad). zdravljenje klopi (dermacentor reticulatus, ixodes ricinus, rhipicephalus sanguineus) infestations. zdravljenje demodicosis (zaradi demodex canis). zdravljenje sarcoptic mange (zaradi sarcoptes scabiei var. canis).

Europäische Union - Slowenisch - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artritis, revmatoidni - imunosupresivi - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Europäische Union - Slowenisch - EMA (European Medicines Agency)

alnylam netherlands b.v. - givosiran - porphyrias, jeter - različne zdravljene bolezni prebavil in presnove izdelki - zdravljenje akutna okvara porphyria (ahp) pri odraslih in mladostnikih, starih 12 let in več.

Europäische Union - Slowenisch - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belantamab mafodotin - multiple myeloma - antineoplastična sredstva - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Europäische Union - Slowenisch - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemija, srčna celica - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Europäische Union - Slowenisch - EMA (European Medicines Agency)

stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastična sredstva - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).